📢 Exciting News!! UPyTher received the prestigious Gerard & Anton Award as 'One to Watch' startup company in the Brainport Region. The award committee described our work as truly life-changing for patients with peritoneal cancer. We feel honored to be rated among the 10 most promising companies in the Brainport Region. Innovation Origins NL | Gerard & Anton | The Gate | Stimulus Programmamanagement | Metropoolregio Eindhoven | Patricia Y.W. Dankers | Peter-Paul Fransen | Frans Lichtenauer
Over ons
UPyTher, a spin-off company of the Eindhoven University of Technology, is a preclinical stage company and develops long-acting hydrogel-drug formulations for the treatment of peritoneal diseases – a field that comes with specific requirements when it comes to local intraperitoneal drug delivery and treatment. The company was founded in 2020 with the vision to increase the treatment options and outcome for patients with peritoneal carcinomatosis and turn it into a treatable disease. Our mission is to set a new standard of care in peritoneal oncology by making intraperitoneal therapy simple, safe, and effective.
- Website
-
www.upyther.com
Externe link voor UPyTher
- Branche
- Productie medische apparatuur
- Bedrijfsgrootte
- 2-10 medewerkers
- Hoofdkantoor
- Eindhoven
- Type
- Particuliere onderneming
- Opgericht
- 2020
Locaties
-
Primair
Routebeschrijving
Eindhoven, NL
Medewerkers van UPyTher
Updates
-
UPyTher warmly welcomes Helmuth van Es on its Board of Advisors. Helmuth brings over 30 years of experience in the biotech industry. His addition to the team will boost the growth of UPyTher and advancement of the company's lead product UPT-211 to the clinical stage.
-
UPyTher announces seed financing to advance the treatment of peritoneal cancer. For more information read the full article or visit our brand new website: www.upyther.com
-
Proud to be a member of the SBMC community. A major shoutout to SBMC for supporting UPyTher on its journey to make peritoneal cancer a treatable disease.
🚀 Exciting Innovation in Cancer Treatment! 🚀 We're thrilled to share UPyTher's groundbreaking approach to combat peritoneal carcinomatosis (PC), a major challenge in oncology. Their unique hydrogel formulations offers a slow-release system that maintains therapeutic levels inside the peritoneal cavity directly at the tumor site, promising enhanced treatment outcomes for patients with peritoneal metastases of colorectal, ovarian, and gastric cancers. Discover more about how UPyTher, a spin-off from Technische Universiteit Eindhoven, is revolutionizing chemotherapy and advancing peritoneal oncology with a more effective and less invasive treatment!
-
Funding from Europe and the Province of North Brabant for Eindhoven based UPyTher and SupraPolix BV to bring novel and improved therapy to patients with peritoneal cancer, with a total budget of EUR 2.8 million. SupraPolix develops tailored injectable hydrogel gel solutions for various medical applications. Building on this hydrogel technology UPyTher is pioneering an innovative treatment for patients with peritoneal cancer that enables a very efficient delivery of medicines into the peritoneal cavity. Within the project INJECTOGELS SupraPolix and UPyTher work together to scale-up the production processes of these injectable gels and confirm their safe use as drug delivery platform for intraperitoneal therapy. At the end of the project, UPyTher’s first product for intraperitoneal therapy can be manufactured according to regulatory standards and is supported with a robust nonclinical data package that allows clinical evaluation for patients with peritoneal metastases from colorectal origin. Stimulus Programmamanagement | UPyTher | SupraPolix BV
-
-
Incredibly proud and honoured by the recognition of KWF Kankerbestrijding for our work together with Patricia Y.W. Dankers at the Eindhoven University of Technology. With this support from KWF, UPyTher can expand its activities to a treatment for patients with metastatic ovarian cancer. The project hallmarks the joint effort of the Dankerslab & UPyTher to take a materials-approach to overcome today's drug-challenges in peritoneal oncology.
The KWF Kankerbestrijding awarded 429,200 euros for research into drug delivery to fight metastatic ovarian cancer! This research will be set up and conducted by Dankerslab and UPyTher together.👏 "It is very exciting that The KWF honours a research proposal with the TU/e and a spin-off as main applicants," says Patricia Dankers, professor of Biomaterials. Read more about the groundbreaking research of UPyTher 👉 https://lnkd.in/eyF2dAZq
-
-
It's a wrap! Five days packed with Slush experiences have come to an end. We return home energized and inspired by all the fellow entrepreneurs we have met, inspiring talks we have seen, and new leads to follow up for UPyTher. If you feel you have unfinished business with us...drop a DM! Thanks to 4TU.Federation | Netherlands Enterprise Agency (RVO) | Eindhoven University of Technology | Brabantse Ontwikkelings Maatschappij (BOM) | for making it happen! UPyTher | Frans Lichtenauer | Peter-Paul Fransen | Geert van Almen
-
-
Do we see you at Slush this week? Peter-Paul Fransen | Frans Lichtenauer | Geert van Almen | The Gate | 4TU.Federation | Slush
Here's to all fellow 'Slushies' that want to know more about UPyTher and who are tired of reading through all the company bio's and pitch decks on the Slush event site...We made you a video 😬 Interested? Drop a DM to meet us in Helsinki with 4TU.Federation from 28 Nov - 1 Dec. ...and of course also to everyone else interested in what it is that we do, and why we do it! The Gate | Eindhoven University of Technology | 4TU.Federation | Brabantse Ontwikkelings Maatschappij (BOM) | Slush | UPyTher
-
Only 4 days to go until Slush Helsinki! With Peter-Paul Fransen, Frans Lichtenauer and Geert van Almen
Start-up UPyTher develops a special gel with chemotherapy to treat peritoneal cancer. This is a difficult-to-treat type of cancer that affects more than a million people worldwide each year. Geert van Almen and Peter-Paul Fransen talk about the technology and their company that could save many lives in the future. 4TU.Federation The Gate
Chemo-gel shows promise in the treatment of peritoneal cancer
https://innovationorigins.com
-
UPyTher is crushing it with the Dutch at Slush! On Thursday Nov 9 we met the entire delegation of Dutch startups, 4TU, RVO and ROMs that will attend Slush 2023 in Helsinki. A great afternoon that got us prepped, inspired and hyped. Finland here we come! Do we see you on Nov 28 - Dec 2 in Helsinki at Slush?
-